+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026

  • ID: 5308848
  • Report
  • March 2021
  • Region: Global
  • 150 Pages
  • Kuick Research
UP TO OFF
until Apr 30th 2021

FEATURED COMPANIES

  • Blueprint Therapeutics
  • Boston Pharmaceuticals
  • Daiichi Sakyo
  • Eli Lilly
  • GSK
  • Helsinn

Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026 Report Highlights:

  • Global RET Inhibitors Market Opportunity: > USD 1.5 Billion
  • Global RET Inhibitors Market Absolute Growth : 3900% (2020-2026)
  • RET inhibitors clinical Trials Insight by Company, Country, Indication & Phase
  • RET Inhibitors In Clinical Trials: > 15 Drugs
  • Commercially Available RET Inhibitors: 2 (Retevmo and Gavreto)
  • First RET Inhibitor Approved In 2020: Retevmo 

RET inhibitor therapy market is a novel, unique yet a challenging aspect followed by the oncology researchers for the treatment of different types of cancers. The total cancer mortality rate in the world had increased to such greater percentage that it was of utmost importance to come up with a therapeutic procedure that could effectively eradicate disease causing cells in the human body. Oncology researchers focused towards the development of a novel therapeutic for the patients landed with one of the most innovative and important breakthroughs as the therapy targets one of the most important proto-oncogene responsible for the initiation of cancerous cells inside the body. It has been only few years since the total penetration of RET inhibitor therapy market in the global cancer therapeutics industry and in such short period of time, it has remained successful in emerging as the next strong pillar for the entire cancer therapeutics market, as it targets at the molecular level, which is apparently very less in the global cancer therapeutics market. 

Major biopharmaceutical companies and biotech firms around the world have initiated several strategically important alliances which include partnerships, collaborations and many more, leading to gardening the entire therapy towards launching large number of drugs in the next few years. High inclination of oncology researchers towards the development and expansion of the therapy is also moving the entire market to receive high appreciation rate as it carries the ability to end all the challenges and complexities that were getting highly reported in the global cancer therapeutics market in the form of side-effects. 

The entire research and growth frontiers associated with the therapy development and expansion rate are believed to increase at a higher percentage in the future years, observing the endless applications received from it. In addition, inclination of the therapy towards targeting different types of cancers such as non-small cell lung cancer, breast cancer, pancreatic cancer and many more is also inclining the entire therapy to get recognized as a viable, potential, terrifying market, compared with other cancer therapies available in the market for long period of time. 

As per Global RET Inhibitors Drug Market Opportunity & Clinical Trials Insight 2026 findings, it is estimated that the complete emergence of the therapy at pre-clinical and clinical level has landed hundreds of novel treatment opportunities for the enrolled participants with respect to overall survival rate. Also, extensive amount of investments laid down for the therapy development and expansion worldwide by elite research centers and government bodies will also deliver and exhibit great amount of work that will soon incline the therapy towards passing early stage of development. With large number of investigational drugs in the clinical trial, the therapy is also attaining massive attraction from numerous clinical stage biotech companies focused towards multi-billion dollar investment and collaborations. To conclude, it can be stated that the future of the therapy will be adjoined with massive commercial success as there are several promising candidates in the pipeline. In addition, it is also believed to get transformed into a fundamental approach for the benefit of millions of patients. 

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Blueprint Therapeutics
  • Boston Pharmaceuticals
  • Daiichi Sakyo
  • Eli Lilly
  • GSK
  • Helsinn

1. Introduction to Rearranged During Transfection (RET) Inhibitors
1.1 Overview
1.2 Evolution of RET Inhibitors

2. Role of RET Inhibitors in Cancer

3. RET Inhibitors - Mechanism of Action

4. RET Inhibitors As Non-Small Cell Lung Cancer Therapeutics
4.1 Role of RET Inhibitors in NSCLC
4.2 Ongoing Research & Development
4.2.1 TAS0953/HM06
4.2.2 RXDX-105
4.2.3 BOS172738
4.2.4 TPX-0046

5. RET Inhibitors as Thyroid Cancer Therapeutics
5.1 Impact of RET Inhibition on Thyroid Cancer
5.2 Current Advancements & Research

6. RET Inhibitors in Colorectal Cancer
6.1 RET Gene Inhibition Influencing Colorectal Cancer
6.2 Ongoing Research & Development

7. RET Inhibitors in Other Leading Cancers
7.1 RET Inhibitors in Breast Cancer
7.2 RET Inhibitors in Liver Cancer
7.3 RET Inhibitors in Melanoma
7.4 RET Inhibitors in Hematological Cancers
7.5 RET in Gastric Cancers

8. RET Inhibitors in Combinational Therapy

9. Global RET Inhibitors Market Analysis
9.1 Overview
9.2 Current Market Scenario

10. RET Inhibitors Market Opportunities by Region
10.1 US
10.2 Europe
10.3 Japan
10.4 China

11. Retevmo (Selpercatinib)
11.1 Overview
11.2 Patents & Assignee
11.3 Dosage, Price & Sales Analysis

12. Gavreto (Pralsetinib)
12.1 Overview & Patent Information
12.2 Dosage, Price & Sales Analysis

13. Global RET Inhibitors Clinical Trials Overview
13.1 By Phase
13.2 By Status
13.3 By Region

14. Global RET Inhibitors Clinical Trials Insight By Country, Company & Indication
14.1 Research
14.2 Preclinical
14.3 Phase-I
14.4 Phase-I/II
14.5 Phase-II
14.6 Phase-III

15. Approved & Marketed RET Inhibitors Clinical Insight
15.1 Pralsetinib (Gavreto)
15.2 Selpercatinib (RETEVMO)

16. Global RET Inhibitors Market Trends
16.1 Voroni & Inno N Collaborated to Develop Novel RET Inhibitor Candidate
16.2 Researchers Identified First Mechanism of Resistance to Retevmo (Selpercatinib)
16.3 Helsinn Doses its Investigational RET Inhibitors in First Patient of Phase I/II Trial
16.4 TPX-0046 - Investigational RET Inhibitor Shows Prominent Results in Preclinical Studies

17. Global RET Inhibitors Market Dynamics - Drivers & Challenges
17.1 Global RET Inhibitor Market Drivers
17.2 Challenges for Global RET Inhibitors Market

18. Global RET Inhibitors Market - Future Outlook

19. Competitive Landscape
19.1 Boston Pharmaceuticals
19.2 Blueprint Therapeutics
19.3 Daiichi Sakyo
19.4 Eli Lilly
19.5 GSK
19.6 Helsinn
19.7 Ignyta
19.8 Inno N
19.9 LoxoOncology
19.10 Roche
19.11 Taiho
19.12 Turning Point Therapeutics

List of Figures
Figure 1-1: Global - NSCLC Cancer Frequency by Mutation Types (%)
Figure 1-2: Global - Thyroid Cancer Frequency by Mutation Types (%)
Figure 1-3: Evolution of RET Inhibitors
Figure 2-1: Frequency of RET Mutation in NSCLC & Papillary Thyroid Cancer (%)
Figure 2-2: Frequency of RET Fusion by Medullary Thyroid Cancer Type (%)
Figure 2-3: Frequency of RET Mutation by Cancer Type (%)
Figure 2-4: Roles of RET Inhibitors in Cancer Management
Figure 3-1: Pathways of RET Alteration in Cancer
Figure 3-2: Outline of RET Signaling Pathway & Mechanism of RET Inhibitors
Figure 3-3: Therapeutic Kinase Activity By Selectivity
Figure 4-1: Global - Newly Diagnosed Cases & Deaths related to Lung Cancer (Million), 2020
Figure 4-2: Global - Lung Cancer Share by Type (%), 2020
Figure 4-3: Fusion Partners Required for RET Mutation in NSCLC
Figure 4-4: Activity of RET Inhibitors in RET-Mutated NSCLC
Figure 4-5: Investigational RET Inhibitors for NSCLC
Figure 4-6: TAS0953/HM06 Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 4-7: BOS172738 Phase I Trial - Study Initiation & Expected Completion Year
Figure 4-8: TPX-0046 Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 5-1: Global - Number of Newly Diagnosed Liver Cancer Cases, 2020, 2025 & 2030
Figure 5-2: Global - Number of Newly Diagnosed Liver Cancer Cases (Million), 2020, 2025 & 2030
Figure 5-3: Roles of RET Inhibitors in Thyroid Cancer Management
Figure 5-4: Retevmo Phase III Trial - Study Initiation & Expected Completion Year
Figure 5-5: Retevmo Phase II Trial - Study Initiation & Expected Completion Year
Figure 5-6: Gavreto Phase III Trial - Study Initiation & Expected Completion Year
Figure 6-1: Global - Estimated Newly Diagnosed Colon Cancer Cases (Million), 2020, 2025 & 2030
Figure 6-2: Global - Estimated Colon Cancer Deaths, 2020, 2025 & 2030
Figure 6-3: Global - Estimated Newly Diagnosed Rectum Cancer Cases, 2020, 2025 & 2030
Figure 6-4: Global - Estimated Rectum Cancer Deaths, 2020, 2025 & 2030
Figure 6-5: Mechanism of RET Inhibitors in Colorectal Cancer
Figure 6-6: Retevmo Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 6-7: Gavreto Phase I/II Trial - Study Initiation & Expected Completion Year
Figure 7-1: Global - Number of Newly Diagnosed Breast Cancer Cases (Million), 2020, 2025 & 2030
Figure 7-2: Global - Number of Newly Diagnosed Breast Cancer Cases (Million), 2020, 2025 & 2030
Figure 7-3: Common Types of RET Alterations in Breast Cancer
Figure 7-4: Global - Number of Newly Diagnosed Liver Cancer Cases (Million), 2020, 2025 & 2030
Figure 7-5: Global - Number of Newly Diagnosed Liver Cancer Cases (Million), 2020, 2025 & 2030
Figure 7-6: Global - RET Mutation Frequency by Liver Cancer Type (%), 2020
Figure 7-7: Roles of RET Inhibitors in Liver Cancer Management
Figure 7-8: Global - Number of Newly Diagnosed Melanoma Cases, 2020, 2025 & 2030
Figure 7-9: Global - Number of Newly Diagnosed Melanoma Cases, 2020, 2025 & 2030
Figure 7-10: US - Estimated Newly Diagnosed Blood Cancer Cases by Type, 2020
Figure 7-11: US - Estimated Blood Cancer Deaths by Type, 2020
Figure 7-12: Global - RET Mutation Frequency by Hematological Cancer Type (%), 2020
Figure 7-13: Mechanism of RET Inhibitors in Hematological Cancers
Figure 7-14: Global - Number of Newly Diagnosed Gastric Cancer Cases (Million), 2020, 2025 & 2030
Figure 7-15: Global - Number of Newly Diagnosed Gastric Cancer Cases, 2020, 2025 & 2030
Figure 7-16: Global - RET Mutation Frequency by Gastric Cancer Type (%), 2020
Figure 8-1: Drug Classes Used in Combination with RET Inhibitors
Figure 9-1: Global - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 9-2: Global - Number of Cancer Deaths (Million), 2020, 2025 & 2030
Figure 9-3: Global - NSCLC Drugs Market Size (US$ Billion), 2020 - 2026
Figure 9-4: Global - Thyroid Cancer Drugs Market Size (US$ Billion), 2020 - 2026
Figure 9-5: Global - Cancer Drug Market Size (US$ Billion), 2020 - 2025
Figure 9-6: Global - RET Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 9-7: Global - RET Inhibitors Market by Product (US$ Million), 2020
Figure 9-8: Global - RET Inhibitors Market by Product (%), 2020
Figure 10-1: US - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 10-2: US - Number of Cancer Deaths, 2020, 2025 & 2030
Figure 10-3: US - RET Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 10-4: US - Tyrosine Kinase Inhibitors Market Opportunity (US$ Million), 2020 - 2026
Figure 10-5: US - RET Inhibitors Market Opportunity by 1% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-6: US - RET Inhibitors Market Opportunity by 2% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-7: US - RET Inhibitors Market Opportunity by 3% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-8: US - RET Inhibitors Market Opportunity by 4% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-9: US - RET Inhibitors Market Opportunity by 5% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-10: Europe - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 10-11: Europe - Number of Cancer Deaths, 2020, 2025 & 2030
Figure 10-12: Europe - RET Inhibitors Market Opportunity (US$ Million), 2021 - 2026
Figure 10-13: Japan - Number of Newly Diagnosed Cancer Cases, 2020, 2025 & 2030
Figure 10-14: Japan - Number of Cancer Deaths, 2020, 2025 & 2030
Figure 10-15: Japan - RET Inhibitors Market Opportunity (US$ Million), 2021 - 2026
Figure 10-16: China - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030
Figure 10-17: China - Number of Cancer Deaths (Million), 2020, 2025 & 2030
Figure 10-18: China - Cancer Drug Market Opportunity (US$ Billion), 2020 - 2026
Figure 10-19: China - Tyrosine Kinase Inhibitors Market Opportunity (US$ Billion), 2020 - 2026
Figure 10-20: China - RET Inhibitors Market Opportunity by 1% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-21: China - RET Inhibitors Market Opportunity by 2% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-22: China - RET Inhibitors Market Opportunity by 3% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-23: China - RET Inhibitors Market Opportunity by 4% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 10-24: China - RET Inhibitors Market Opportunity by 5% of Tyrosine Kinase Inhibitors Market (US$ Million), 2021 - 2026
Figure 11-1: Retevmo - FDA Approval & Orphan Designation Year
Figure 11-2: Retevmo - Patent Issue & Expiration Year
Figure 11-3: Retevmo - Price for 60 Capsules & Price Per Unit Capsules of 40mg (US$), March’2021
Figure 11-4: Retevmo - Price for 60 Capsules & Price Per Unit Capsules of 80mg (US$), March’2021
Figure 11-5: Retevmo - Price for 120 Capsules & Price Per Unit Capsules of 80mg (US$), March’2021
Figure 11-6: Retevmo - Recommended Initial & Reduced Dose for Patients with Weight less than 50Kg (mg/day)
Figure 11-7: Retevmo - Recommended Initial & Reduced Dose for Patients with Weight More Than 50Kg (mg/day)
Figure 11-8: Retevmo - Quarterly Sales Value (US$ Million), Q2-Q4, 2020
Figure 12-1: Gavreto - FDA Approval & Orphan Designation Year
Figure 12-2: Gavreto - Patent Issue & Expiration Year
Figure 12-3: Gavreto - Price for 60 Capsules & Price Per Unit Capsules (US$), March’2021
Figure 12-4: Gavreto - Price for 120 Capsules & Price Per Unit Capsules (US$), March’2021
Figure 12-5: Gavreto - Recommended Initial & Reduced Dose for Patients (mg/day)
Figure 13-1: Global - Number of RET Inhibitors Related Clinical Trials by Phase, March’2021
Figure 13-2: Global - Number of RET Inhibitors Related Clinical Trials by Phase (%), March’2021
Figure 13-3: Global - Number of RET Inhibitors Related Clinical Trials by Status, March’2021
Figure 13-4: Global - Number of RET Inhibitors Related Clinical Trials by Status (%), March’2021
Figure 13-5: Global - Number of RET Inhibitors Related Clinical Trials by Region, March’2021
Figure 13-6: Global - Number of RET Inhibitors Related Clinical Trials by Region (%), March’2021
Figure 17-1: Global RET Inhibitors Market Drivers
Figure 17-2: Challenges for Global RET Inhibitors Market
Figure 17-3: US - Daily Treatment Cost Comparison of NSCLC by Kinase inhibitors Drugs (US$), March’2021
Figure 17-4: US - Daily Treatment Cost Comparison of Thyroid Cancer by Kinase Inhibitors Drugs (US$), March’2021

Note: Product cover images may vary from those shown

Loading
LOADING...

  • Boston Pharmaceuticals
  • Blueprint Therapeutics
  • Daiichi Sakyo
  • Eli Lilly
  • GSK
  • Helsinn
  • Ignyta
  • Inno N
  • LoxoOncology
  • Roche
  • Taiho
  • Turning Point Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll